A Study to Evaluate Stress Management and Resiliency Training vs. Treatment as Usual for Major Depression Treatment

Overview

About this study

The primary purpose of this study is to compare outcomes of depressive symptoms (PHQ-9 and HAM-D) over 6 months following an eight-week program of SMART-D therapy + treatment as usual versus treatment as usual for patients with major depression in partial-to full-remission.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Participants will be enrolled for this study from patients attending the Mayo Clinic Depression Center, Mayo Clinic Family Medicine clinics at Rochester and Kasson, MN;, Behavioral Health and Primary Care Clinic at Mayo Clinic Health System, Austin and Albert Lea, MN, with a diagnosis of major depression with a current moderate episode, with PHQ-9 scores 10-23.
  • Participants will be required to be between 25 and 80 years old.
  • Able to speak English.
  • Able to provide written informed consent to participate in the study.
  • Participants must have DSM-V diagnostic confirmation of major depressive disorder (MDD) (American Psychiatric Association 2013). 
  • Participants will continue taking any prescribed medications from their clinical treatment team. 
  • Participants with co-morbid secondary diagnoses of persistent depressive disorder and generalized anxiety disorders will be included in the study.
  • Participants must consent to audio recording of random group sessions which will be disclosed at the final study session.
  • Participants are willing to use the Mayo Clinic Patient Portal for communication purposes during the study.

Exclusion Criteria:

  • Participants with bipolar disorder, active psychosis, active suicidal ideations, and active substance abuse meeting criteria for substance use disorders except nicotine, obsessive compulsive disorder, active panic disorder with agoraphobia or other phobic disorder, active posttraumatic stress disorder, active severe personality disorders will be excluded.
  • Participants with a severe major depressive episode- HAM-D scores ≥ 23.
  • Pregnant women – because of time duration of the study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ashok Seshadri, M.D.

Open for enrollment

Contact information:

Laura Harper B.S.

(507) 255-9352

Harper.Laura1@mayo.edu

Red Wing, Minn.

Mayo Clinic principal investigator

Ashok Seshadri, M.D.

Open for enrollment

Contact information:

Laura Harper B.S.

(507) 255-9352

Harper.Laura1@mayo.edu

Austin, Minn.

Mayo Clinic principal investigator

Ashok Seshadri, M.D.

Open for enrollment

Contact information:

Laura Harper B.S.

(507) 255-9352

Harper.Laura1@mayo.edu

Albert Lea, Minn.

Mayo Clinic principal investigator

Ashok Seshadri, M.D.

Open for enrollment

Contact information:

Laura Harper B.S.

(507) 255-9352

Harper.Laura1@mayo.edu

More information

Publications

Publications are currently not available
.

Mayo Clinic Footer